High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience

详细信息    查看全文

• 作者：B??hm ; Alexandra ; Piribauer ; Maria ; Wimazal ; Friedrich ; Geissler ; Klaus ; Gisslinger ; Heinz ; et. al.
• 关键词：AML ; Consolidation chemotherapy ; High dose ARA-C ; Toxicity
• 刊名：Leukemia Research
• 出版年：2005
• 出版时间：June, 2005
• 年：2005
• 卷：29
• 期：6
• 页码：609-615
• 全文大小：117 K

文摘

High dose intermittent ARA-C (2 × 3 g/m² i.v., days 1, 3, 5) = HiDAC was introduced as consolidation in AML by the CALGB-group in 1994. We treated 44 de novo AML patients in CR with up to four cycles of HiDAC (four cycles: 56.8 % ; three cycles: 22.7 % ; two cycles: 6.8 % ; one cycle: 13.7 % ). Median duration of aplasia (ANC < 0.5 × 10⁹/l) was 12 days. Neutropenic fever occurred in 38.6 % of the patients during the first, 52.6 % during the second, 45.7 % during the third, and in 40 % during the fourth cycle. Non-hematologic toxicity was tolerable. The median overall- and disease-free survival were 19.3 and 11.3 months, respectively. The best outcome was seen in patients aged <40 years. These results confirm that HiDAC is a safe and effective consolidation in AML.